| ||||||||||||||
|
|
|||||||||||||
University Department of Anaesthesia, Critical Care and Pain Management, Leicester Royal Infirmary, Leicester, United Kingdom
Address correspondence and reprint requests to D. G. Lambert, PhD, University Department of Anaesthesia, Critical Care and Pain Management, Leicester Royal Infirmary, Leicester, LE1 5WW, UK. Address e-mail to DGL3{at}le.ac.uk
Urotensin II is a novel endogenous vasoconstrictor. There are no data describing cerebrospinal fluid (CSF) concentrations in humans. Therefore, in this study, we aimed to quantify and compare plasma and CSF urotensin II concentrations in patients with essential hypertension and matched controls. Twenty male patients (10 receiving >6 mo of treatment for essential hypertension and 10 normotensive controls scheduled to undergo urological surgery under spinal anesthesia) were recruited into this single-blinded cohort study. Plasma and CSF urotensin II concentrations were measured by radioimmunoassay, along with mean arterial blood pressure (MAP), before admission, on the day of admission, and immediately before anesthesia. CSF and plasma urotensin II concentrations were low. Median (range) values in CSF for all 20 patients were significantly lower than plasma by
15% (19.0 pg/mL [10.624.9 pg/mL] compared with 22.3 pg/mL [17.728.4 pg/mL]; P = 0.004). There were no significant differences between normotensive and hypertensive patients in either CSF or plasma concentrations. However, there was a significant positive correlation between average MAP and CSF urotensin II concentrations (r2 = 0.44; P = 0.036) in the hypertensive group.
IMPLICATIONS: Urotensin II is the most potent known endogenous human vasoconstrictor. In this pilot study, we report for the first time that cerebrospinal fluid levels are smaller than plasma levels and that there may be some association with increased blood pressure.
This article has been cited by other articles:
![]() |
A. D. Leonard, J. P. Thompson, E. L. Hutchinson, S. P. Young, J. McDonald, J. Swanevelder, and D. G. Lambert Urotensin II receptor expression in human right atrium and aorta: effects of ischaemic heart disease Br. J. Anaesth., April 1, 2009; 102(4): 477 - 484. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. S. Abdel-Razik, R. J. Balment, and N. Ashton Enhanced renal sensitivity of the spontaneously hypertensive rat to urotensin II Am J Physiol Renal Physiol, October 1, 2008; 295(4): F1239 - F1247. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Cowley, J. P. Thompson, P. Sharpe, J. Waugh, N. Ali, and D. G. Lambert Effects of pre-eclampsia on maternal plasma, cerebrospinal fluid, and umbilical cord urotensin II concentrations: a pilot study Br. J. Anaesth., October 1, 2005; 95(4): 495 - 499. [Abstract] [Full Text] [PDF] |
||||
|